Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin

被引：0
|
作者：
Ritter, W [1 ]
Ochmann, K [1 ]
Muck, W [1 ]
Kuhlmann, J [1 ]
机构：
[1] BAYER AG,CLIN PHARMACOL,D-42096 WUPPERTAL,GERMANY
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 1997年 / 355卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：477 / 477
页数：1
相关论文
共 50 条
  • [1] Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin
    Muck, W
    Ritter, W
    Ochmann, K
    Unger, S
    Ahr, G
    Wingender, W
    Kuhlmann, J
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1997, 35 (06) : 255 - 260
  • [2] The HMG-CoA reductase inhibitor cerivastatin enhances the nitric oxide bioavailability of the endothelium
    Berkels, R
    Nouri, SK
    Taubert, D
    Bartels, H
    Roesen, P
    Roesen, R
    Klaus, WF
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 42 (03) : 356 - 363
  • [3] Biopharmaceutical profile of cerivastatin, a novel HMG-CoA reductase inhibitor
    Muck, W
    Ochmann, K
    Mazzu, A
    Lettieri, J
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 130 - 130
  • [4] Biopharmaceutical profile of cerivastatin:: a novel HMG-CoA reductase inhibitor
    Mück, W
    Ochmann, K
    Mazzu, A
    Lettieri, J
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1999, 27 (03) : 107 - 114
  • [5] Cerivastatin: the low-dose HMG-COA reductase inhibitor
    Tikkanen, MJ
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (01) : 161 - 166
  • [6] Cerivastatin approval expands HMG-CoA reductase inhibitor choices
    不详
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (16) : 1793 - 1793
  • [7] Cerivastatin, a novel HMG-CoA reductase inhibitor: Efficacy and tolerability
    Schmage, N
    Cagatay, M
    Park, SM
    Lommerzheim, A
    Schopen, U
    HERZ KREISLAUF, 2000, 32 (7-8): : 242 - 252
  • [8] Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor
    von Keutz, E
    Schlüter, G
    AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (4B): : 11J - 17J
  • [9] Cerivastatin (BAY w 6228):: A novel HMG-CoA reductase inhibitor
    Kuhlmann, J
    Mück, W
    Bischoff, H
    von Keutz, E
    Llewellyn, M
    CARDIOVASCULAR DRUG REVIEWS, 1998, 16 (03): : 236 - 263
  • [10] EFFECT OF FOOD ON THE BIOAVAILABILITY OF ATORVASTATIN, AN HMG-COA REDUCTASE INHIBITOR
    RADULOVIC, LL
    CILLA, DD
    POSVAR, EL
    SEDMAN, AJ
    WHITFIELD, LR
    JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (10): : 990 - 994
12345